Only 27 women in the trial, but this sounds impressive to me. But then, I'm easily impressed... :)
Public Release: 30-Jan-2012
 Journal of Immunotherapy
4-week vaccination regimen knocks out early breast cancer tumors, Penn researchers report
Researchers at the Perelman School of Medicine at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient's own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ, an early breast cancer.
 National Institutes of Health, Harrington Foundation, Pennies-in-action.org, Mistler Foundation
Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
From: uphs.upenn.edu 
...
Czerniecki and colleagues enrolled 27 women with HER2-positive DCIS. They isolated specialized white cells from the patients’ blood using standard apheresis techniques similar to the blood donation process. Once isolated, the researchers activated the dendritic cells, which are key regulators of the immune system, and primed them with small pieces of the HER2/neu protein in Penn’s Clinical Cell and Vaccine Production Facility. Each patient then received four shots, one week apart, of their personalized anti-HER2 vaccine. And two weeks later patients had surgery to remove any remaining disease, which is standard care for DCIS patients.
... |
